🔗 Share this article

While America proceeds with sweeping changes to its vaccination recommendations, a particular individual appears in a surprising turn: Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by questioning Covid shots throughout the global health crisis and has zeroed in on potential deaths after Covid vaccination in her brief tenure at the FDA.

Scheduled Changes to Childhood Immunization Program

Agency leaders were set to announce major revisions to the childhood vaccination calendar earlier this month, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US out of step with many the world with insufficient data for improved outcomes. This reveal has been pushed back until the coming year.

Instead of the director of the vaccine center, Høeg is scheduled to address the audience at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to lead the division this calendar year.

A Shift at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon reevaluating already-approved immunizations at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric immunization guidelines in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

In her initial public appearances, she has continued to focus on immunizations – typically the domain of Dr. Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

The appointee has no apparent experience in drug development, approval processes or leadership, which has been typical for former directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“It seems she lacks to have the necessary background” for running the drug-regulation department, stated Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a major agency. She is not an expert in industry regulation.”

Former directors of CBER would “grasp regulatory frameworks and the research of medication creation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that previous people who led CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she stated.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office authorizes a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these must be managed,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial management component to the role, which oversees more than 5,000 employees. “It is a enormous leadership role, if you execute it properly,” she concluded.

Response and Contentious Policies

Regarding inquiries about Høeg’s fitness for the role and whether this appointment represents greater collaboration among FDA leaders on immunizations, a spokesperson responded that the “questions are based on inaccurate presumptions”.

“Her resume is consistent with the responsibilities of her position,” the representative explained, noting the months Dr. Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a controversial expedited drug-approval program that allegedly concerned her predecessors. “By what process are these medications being selected for this expedited pathway? Who takes the decisions?” Dr. Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration appears to be shifting towards less stringent oversight of all drugs, aside from shots.”

Documented Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if troubling, history, Howard have noted. She published a research paper using unconfirmed crowd-sourced reports to estimate the rate of myocarditis after COVID-19 immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the new administration encompassed altering guidelines for new vaccines and discontinuing “non-essential” immunizations, she stated following the vote on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of excluding teenage boys from getting COVID-19 vaccinations.

“She’s an thorough dogmatist who begins with her beliefs and works backwards to fit the evidence in a very misleading, dishonest manner,” Howard said.

Taking Control and a “Push for Payback”

Høeg joined fellow skeptics, {like|